Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as NeoRecormon
r-HuEPO · 1 trial · 1 indication
Response to treatment was defined as an increase of greater than (\>) 1 gram per deciliter (g/dL) in hemoglobin level (irrespective of the need of transfusion) from Baseline value at Week 4.
| Arm | Type | Description |
|---|---|---|
| r-HuEPO | EXPERIMENTAL | Anemic cancer participants will receive r-HuEPO for 4 weeks. |
| Name | Type | Description |
|---|---|---|
| r-HuEPO | DRUG | All participants will receive r-HuEPO for 4 weeks, at a dose of 10000 international units per day (IU/day) according to 6 days/week schedule for first 2 weeks and at a dose of 10000 IU/day according to 3 days/week schedule (participants with response to treatment at end of Week 2) or according to 6 days/week schedule (participants without response to treatment at end of Week 2) for next 2 weeks. |
Inclusion Criteria: * Histological or cytological confirmed cancer * Participants who are treated with at least first line chemotherapy * Hemoglobin less than (\<) 11 grams per deciliter (g/dL) * Participants able to receive iron supplement, if necessary Exclusion Criteria: * History of hypersens...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 2 | PHASE3 | Luspatercept |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Elritercept |
| Disc Medicine, Inc. | IRON | 2 | PHASE2 | DISC-0974 |
| Akebia Therapeutics, Inc. | AKBA | 2 | PHASE3 | Vadadustat |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | APG-5918 |
| Bayer | BAYRY | 1 | - | Molidustat |
r-HuEPO is used for anemia, specifically in anemic cancer patients treated with chemotherapy. It is a recombinant human erythropoietin being developed by Roche Holding AG. The drug is currently in Phase 3 clinical development for this indication.
r-HuEPO is a recombinant human erythropoietin, which targets the erythropoietin receptor to stimulate red blood cell production. This mechanism helps treat anemia by increasing hemoglobin levels in patients.
r-HuEPO is developed by Roche Holding AG, a multinational healthcare company. Roche's stock is traded under the ticker RHHBY on the OTC market. The drug is being studied for the treatment of anemia in cancer patients undergoing chemotherapy.
r-HuEPO is in Phase 3 clinical development. It is an investigational drug, not yet approved by regulatory authorities. A Phase 3 study has been completed to evaluate its safety and efficacy in anemic cancer patients receiving chemotherapy.
r-HuEPO has one completed Phase 3 clinical trial, NCT02767765, titled 'A Study of Recombinant Human Erythropoietin Beta (NeoRecormon) in Anemic Cancer Participants Treated With Chemotherapy.' This trial enrolled 61 participants in Italy and was completed.
Yes, r-HuEPO is also known as NeoRecormon, a brand name for recombinant human erythropoietin beta. The clinical trial NCT02767765 specifically refers to NeoRecormon, confirming that r-HuEPO and NeoRecormon are the same drug.